First look: new blood disorder drug tested in healthy volunteers
NCT ID NCT06581627
First seen Jan 11, 2026 · Last updated Apr 09, 2026 · Updated 12 times
Summary
This early-stage study tested a single dose of a new oral medicine called etavopivat in 24 healthy Chinese volunteers. The main goal was to see how the drug moves through and is processed by the body (pharmacokinetics) and to check its initial safety and tolerability. The results will help researchers understand how to dose the drug for future studies in people with sickle cell disease or thalassemia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Hospital
Beijing, Beijing Municipality, 100730, China
Conditions
Explore the condition pages connected to this study.